PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Ageing Population Drives Demand for IVD Devices in Australia Finds Frost & Sullivan - The market to grow at a CAGR of 6.0 per cent despite regulatory challenges - DrugDiscovery.Frost.com
Ageing Population Drives Demand for IVD Devices in Australia Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Sydney, Australia, 2011/08/04 - The market to grow at a CAGR of 6.0 per cent despite regulatory challenges - DrugDiscovery.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

There is high demand for in-vitro diagnostic (IVD) devices in Australia, as the country's ageing population requires more IVD-based tests. With close to 90 per cent of the IVD products being imported, the Government has implemented new regulatory changes to ensure that imported products are of superior quality.

New analysis from Frost & Sullivan (drugdiscovery.frost.com), In-vitro Diagnostics Market Outlook in Australia, finds that the market earned revenues of US$468 million in 2010 and estimates this to reach US$703.4 million in 2017.

"The new regulations are likely to increase the regulatory and product approval costs, which will have an immediate impact in this market," says Frost & Sullivan Industry Analyst Arun AK. "However, this is likely to boost customer confidence in the products and improve the quality of IVD testing in a longer run."

The IVD market in Australia is relatively small and likely to witness high growth in the molecular testing, point-of-care testing (POCT) and self-monitoring of blood glucose (SMBG) segments.

"Rising acceptance of molecular diagnostic tests encourages innovative regional companies to develop innovative tests," notes Arun. "However, the newly implemented regulatory framework, which forces all IVDs to undergo pre-market regulatory assessment in accordance with their level of risk, is likely to result in low turnover of products."

In market segments experiencing low growth, this regulation might lead to product withdrawals, resulting in limited product choices in the market. The financial burden placed on the manufacturers by regulatory changes is likely to restrain them from introducing novel tests in the market.

Though the regulatory changes will have a financial impact on the IVD companies, manufacturers can focus on introducing products in high-growth markets such as molecular testing to counter or minimise this effect. The existing high volume of tests requires laboratories to invest in automating their clinical testing process to manage such demand.

This will boost the adoption of integrated automation in the country. As price-based competition is increasing in the market, global companies can seek local collaborations to manufacture their products in Australia to gain a cost advantage and maintain their high profit margins.

If you are interested in more information on this study, please send an email to Donna Jeremiah, Corporate Communications, at djeremiah[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.

In-vitro Diagnostics Market Outlook in Australia is part of the Clinical Diagnostics Growth Partnership Services program, which also includes research in the following markets: In-vitro Diagnostics (IVD) Market Outlook in South Korea, European Tissue Diagnostics Market and European Microarrays Market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

In-vitro Diagnostics Market Outlook in Australia / P4B8

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Ageing Population Drives Demand for IVD Devices in Australia Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Donna Jeremiah / Carrie Low 
+603-6204-5832 / +603-6204-5910 djeremiah[.]frost.com / carrie.low[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)